Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUTCH Weight Control in Atrial Fibrillation Study (DUTCH-WAIST)
2022-501392-81-00Phase 4Authorised
- Sponsor
- Rijnstate
- Start
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Atrial fibrillation (AFib) and obesity comparing Semaglutide with Placebo (2 arms). Primary endpoints: Ranked 1-year rhythm outcome status and Composite AF rhythm and safety endpoint at 12 months. Planned start Jun 2024; status: authorised.
02
Drugs
03
Conditions
Atrial fibrillation (AFib)obesity
Beyond the preview
Go deeper on 2022-501392-81-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501392-81-00.